Professor Liu Xingguo, was honored as “Distinguish Youth Foundation” of National Natural Science Foundation, Chief Scientist of the National Key Research and Development Program of China, 1st finisher of the first prize of the Guangdong Science and Technology Award in Natural Science, The Shulan Medicine Youth Award by the Academician Shusen Lanjuan Talent’ Foundation, “2016 Stem cell Young Investigator Award” from Chinese Society for Cell Biology and “Young Bioenergeticist Award” of the International Biophysical Society. He is the Executive Editor of Science Bulletin, the council member of the Asian Society for Mitochondrial Research and Medicine, and the council member of the Biophysical Society of China. Professor Liu has published 60 papers, which has been cited for more than 3000 times. Since 2015, he has published 27 research papers as corresponding author (2 IF>30, 21 IF>9), such as Cell Metabolism (2016、2018), Nature Metabolism, Nature Structural & Molecular Biology, Nature Communications, Science Advances (2019, 2022), Advanced Science, Hepatology. Among his papers, 3 were recommended by F1000, 6 were chosen as cover story. He obtained 8 authorized patents (including one PCT). Professor Liu has been the invited speakers in more than 70 international conferences.
The study of pluripotent stem cells has been mostly focused on molecular biology. However, organelle remodeling and metabolic controlling in cell fate determination remains unclear. After establishing his team since 2010, Prof. Xingguo Liu has been focusing on this direction, and achieved novel findings both in physiological and pathological conditions. On one hand, he discovered the rules of mitochondrial/metabolic regulation of nuclear epigenetics such as the law of mitochondrial oxygen ion signals regulating DNA and histone methylation, a new concept of the " epigenome-metabolome-epigenome" cascade, and organelle remodeling and regulating new functions of pluripotency. On the other hand, he clarified the new pathology of mitochondrial/metabolic diseases such as apoptosis or ferroptosis of liver cells from patients with mitochondrial DNA depletion syndrome, and iPSC technology to drug toxicity research.